(CATB) - Earnings & Price History

CATB: - 1.935, $44.96M, -0.11 (-5.15%)

Sector: Healthcare - Industry: Biotechnology

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient; and CAT-2003 that has completed Phase IIa trials for the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001 that is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has collaboration agreements with dystrophy association for th

Past CATB reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-16AMC-0.521.551.71.751.551.752.94%-11.43%-8.82%1.41M
2017-03-01AMC-0.521.171.191.171.151.22-1.68%-1.68%362.71K
2017-02-28AMC-0.521.191.21.231.171.232.50%-3.25%-0.83%181.74K
2016-11-10AMC-0.654.454.224.774.45.1613.03%▲-6.71%5.45%186.21K
2016-08-11AMC-0.655.055.344.184.015.25-21.72%20.81%-5.43%154.73K
2016-05-12AMC-0.644.914.454.194.96-5.84%17.18%10.34%51.30K
2016-03-02AMC-0.694.494.44.524.354.642.73%-0.66%2.05%85.38K
2015-11-12AMC-0.647.037.647.576.757.51-0.92%▲-7.13%-7.98%20.54K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades